Press releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Apr 26, 2022
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.87 per common share, payable on June 30, 2022 to holders of record on June 9, 2022....
-
Apr 26, 2022
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has been recognized by Forbes as one of the top employers in the U.S. for...
-
Apr 25, 2022
Developed with novel dye technology and AI guidance, new BD Horizon RealYellow™ 586 Reagents have potential to accelerate discovery and drug development in oncology, autoimmune disorders and...
-
Apr 22, 2022
Institute will drive sustainable innovation in three areas of environmental stewardship, furthering progress toward the company's 2030+ environmental, social and governance (ESG) commitments...
-
Apr 7, 2022
BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will report financial results for its second quarter of fiscal year 2022 on Thursday, May 5, 2022. A news release will be...
-
Apr 1, 2022
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has completed its spinoff of Embecta Corp. (embecta) (NASDAQ: EMBC), which...
-
Mar 31, 2022
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Alberto Mas has informed the company of his intent to retire from BD, effective at...
-
Mar 30, 2022
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company today announced the early results and pricing terms of Morgan Stanley & Co. LLC's ("Morgan Stanley")...
-
Mar 30, 2022BD Rhapsody™ TCR/BCR Multiomic Assay speeds discovery in autoimmune disorders, immuno-oncology and infectious diseases
FRANKLIN LAKES, N.J. (Mar 30, 2022) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, recently released the BD Rhapsody™ TCR/BCR Multiomic Assay,...
-
Mar 25, 2022
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has been named to Newsweek's inaugural list of "America's Most Trusted...